Cyclic chemotherapy in lymphoma

Abstract

This study evaluates the cyclic use of a combination of four drugs—cyclophosphamide, vincristine, procarbazine, and prednisone in 12 patients with generalized lymphosarcoma (LSA) and 11 patients with reticulum cell sarcoma (RCS). Seven patients with LSA achieved a category I response, and of these, 4 are clinically free of disease. In the RCS group, only one achieved a category I response. Myelosuppression was severe in 4 patients (17%) and may have contributed to their deaths from infectious complication. A high incidence of extranodal involvement in this group of patients appeared to correlate with the low incidence of useful therapeutic responses.